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Abstract
Biotargeted nanomedicines have captured the attention of academic and industrial scientists who
have been motivated by the theoretical possibilities of the ‘magic bullet’ that was first
conceptualized by Paul Ehrlich at the beginning of the 20th century. The Biotargeting Working
Group, consisting of more than 50 pharmaceutical scientists, engineers, biologists and clinicians,
has been formed as part of the National Cancer Institute’s Alliance for Nanotechnology in Cancer
to harness collective wisdom in order to tackle conceptual and practical challenges in developing
biotargeted nanomedicines for cancer. In modern science and medicine, it is impossible for any
individual to be an expert in every aspect of biology, chemistry, materials science, pharmaceutics,
toxicology, chemical engineering, imaging, physiology, oncology and regulatory affairs. Drawing
on the expertise of leaders from each of these disciplines, this commentary highlights six tenets of
biotargeted cancer nanomedicines in order to enable the translation of basic science into clinical
practice.
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Nanotechnology has been applied to cancer to enhance the utility of US FDA-approved
chemo-therapeutics. Practical benefits of nanoparticle-based chemotherapeutics include
increased drug solubility, reduced toxicity to healthy organs, increased tumor accumulation,
and protection of the payload from premature metabolism and degradation. Nanoparticles
can further be engineered to target specific tumor cells that express particular cell surface
molecules. The selection of appropriate targets, component materials, formulation strategies
and characterization methods are critical to achieving successful outcomes. Manufacturing
and quality control requirements that are mandated by regulatory bodies are also important
factors to clinical translation. Finally, market acceptance, pricing and reimbursement issues
must be considered. As one embarks on the creation and development of biotargeted
nanomedicines for cancer, six important tenets should guide the process.
Tenet 1: sights on the target
Biotargeted nanomedicines are defined as nanoparticles containing a drug and/or imaging
agent administered to the body and targeted to a specific organ [1], tissue [2], cell [3] or
subcellular [4] compartment in order to treat [5] or diagnose [6,7] disease, or both (Figure 1)
[8,9].
Biotargeting is afforded by the use of targeting ligands on the surface of nanoparticles,
including small molecules [10], peptides [11], antibodies [12], affibodies [13] and aptamers
[14]. These particles, when loaded with drugs, biologics, nucleic acids or imaging agents,
have shown tremendous utility as in vitro diagnostics and as therapies in animal models of
cancer. Translating such nanoparticles into biotargeted nanomedicines requires that they
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confer improved efficacy or safety in patients. Challenges and possible solutions are
discussed herein.
Biotargeted nanomedicines have the potential to transform the diagnosis and treatment of
many human diseases; however, selection of the appropriate target is critical for successful
outcomes. While some early progress has been achieved, the full realization of the impact of
this approach will depend largely on the determination of suitable clinical applications.
Biotargeted nanomedicines can be developed at the level of the drug (molecular targeted
therapy such as Gleevec®; Novartis Pharmaceuticals Corporation, NJ, USA) or at the level
of the delivery system, which is the primary focus of this article.
Biotargeted nanoparticles have the potential to substantially improve the therapeutic index
of their payloads by increasing drug potency via selective delivery to target cancer cells or
tumor stroma, thereby reducing their systemic toxicity and undesired off-target effects.
Twenty nanomedicines have been approved by the FDA [15] and there are currently four
targeted nanomedicines under clinical investigation, all in the area of cancer: BIND-014
[101], CALAA-01 [102], MBP-426 [103] and SGT-53 [104]. BIND-014 is a prostate-
specific membrane antigen-targeting PLGA nanoparticle containing docetaxel. CALAA-01
is a transferrin receptor-targeting cyclodextrin-based nanoparticle containing siRNA
directed against the M2 subunit of ribonucleotide reductase. MBP-426 is a transferrin
receptor-targeting liposome containing oxaliplatin. SGT-53 is a transferrin receptor-
targeting liposome containing plasmid DNA encoding p53.
It is noteworthy that, among the four ongoing trials, there are three different classes of
therapeutics represented: small molecules, siRNA and DNA. It is also noteworthy that three
of the four formulations target the transferrin receptor. This receptor is often targeted
because it is one of the most abundant receptors on the cell membrane, is released from
clathrin-coated pits by endosomal acidification and recycles rapidly back to the cell
membrane; together, these features promote high-efficiency uptake into the cell. Both native
transferrin and antibodies to the transferrin receptor can be conjugated to nanoparticles to
facilitate internalization. Although multiple therapeutic modalities are being advanced
through clinical trials, there clearly remains a shortage of validated receptors to target. The
use of defined criteria represents a novel approach to identifying and validating targetable
biomarkers [16]. Among the criteria considered were extracellular localization of the target,
diffuse upregulation of the target throughout tumor tissue and upregulation of the target in
most patients.
Several features are desirable for targeting, but the identification of receptors that satisfy all
of these criteria remains difficult. First, exclusive presentation (e.g., clusters of
differentiation markers within immune cell subpopulations) or at least marked upregulation
(e.g., EGF receptor, HER2, MUC1 on cancer cells with a tumor:normal cell expression ratio
of at least 10:1) of the receptor enables the nanomedicine to discriminate between the
targeted cell and other cells in the body. Second, receptor function in the diseased state must
be considered when designing a targeting strategy. Examples include sensitivities to known
ligands, crosstalk between downstream signaling pathways, mechanisms of receptor
internalization and/or turnover, and receptor saturation and/or downregulation after repeated
doses [17]. Third, although releasing small molecules in close proximity to the target cell
can be beneficial in the case of small-molecule therapeutics, particle uptake by receptor-
mediated processes is essential for nucleic acid-based therapies. Indeed, it has been shown
that the principal advantage of targeted nanoparticles is related to uptake by cancer cells
rather than overall tumor localization [18,19]. Consequently, optimization of particle
internalization will probably enhance the specificity and efficacy of nanomedicines.
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Tenet 2: leaping biological hurdles
The validation of additional targets is important, but the complexity of tumor biology must
also be recognized [20]. Recent evidence indicates that tumors are composed of highly
interactive and cooperatively functioning cellular communities. These cell subpopulations
modulate one another’s biological characteristics, such as growth rate, metastatic ability and
sensitivity to anticancer therapy [20,21]. In this regard, tumors can be regarded as self-
generated heterogeneous cell populations contained within a permissive tumor
microenvironment that is a complex system of many cell types. Collectively, these diverse
cells make up the complex organ system of solid tumors, which includes vasculature, stroma
and tumor parenchyma, and contribute dynamically to tumor progression, metastasis and
resistance to therapy [22].
One of the fundamental considerations for biotargeting is the determination of which cell
type to target: endothelium, tumor cells, stroma or a combination of cell types. Our currently
limited understanding of the repertoire of clinically relevant, targetable cellular receptors (or
other plasma membrane proteins) and their interactions, cell surface densities, shedding
status, turnover, internalization rates and dynamics hampers translation. Further fundamental
biological studies are needed to understand these processes in both cancer and healthy cells,
since the majority of tumor targets are expressed at some level in healthy cells. Basic
science will inform applied science not only at the level of the cell surface but also at the
level of the tumor–organ system.
Owing to the intrinsic heterogeneity of tumors and the multiple barriers within tumors,
robust biotargeting has proven to be a formidable challenge for the most common forms of
solid cancer. Receptor-targeted or ligand-enabled nanomedicines and imaging agents must
travel from the systemic circulation into the tumor vas-culature, penetrate into the tumor
parenchyma, diffuse deeply into the hypoxic core of the tumor and discriminate their target
cells from healthy neighboring cells (Figure 2).
Several physical barriers limit the efficacy of tumor penetration and delivery by
nanomedicines directed against solid tumors, including heterogeneous circulation caused by
the abnormal and irregular architecture of tumor vasculature, intratumoral vascular
hyperpermeability contributing to increased interstitial pressure in the targeted tumors that
substantially reduces the convective transport of nanoparticles into the mass, and impaired
diffusion in the context of an unusual, highly dense extracellular matrix in the tumor
microenvironment. It has been postulated that these barriers are responsible for the modest
survival benefit that has been observed using FDA-approved nanotherapeutics, as delivery
of insufficient quantities of drug in the tumor core can lead to resistance and/or incomplete
treatment [23]. Accordingly, the development of innovative strategies aimed at abnormal
tumor vasculature and matrix barriers are needed as components of a multipronged
treatment strategy in which nanomedicines play a role. The use of antiangiogenic therapies
and matrix-modifying enzymes can normalize the vascular network and can even be
combined with cytotoxic reagents to improve efficacy [24].
Novel strategies are being pursued to engineer solutions through multistage nanoparticle
delivery [25]. The inclusion of tumor micro-environment-sensitive shells allows for site-
specific activation of the particles. One example of this approach combined the natural
ability of approximately 100-nm particles to accumulate in tumors (owing to enhanced
permeation and retention by the leaky tumor vasculature) with the ability of smaller particles
(~10 nm) to penetrate more deeply into the tumor tissue by including a tumor protease-
responsive peptide [26]. Related approaches have demonstrated the active biotargeting
domains in the presence of such matrix metalloproteinases [27] or in response to decreased
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pH in the hypoxic tumor core [28]. Engineering efforts will surely benefit from and
hopefully synergize with studies that enhance our understanding of tumor biology.
Tenet 3: these are not tablets
Even if the biology were simple, the ability to control the material properties of
nanomedicines remains a major obstacle to the realization of the potential of medical
nanotechnology. Many additional parameters, such as physicochemical properties, are
critical to the translation of nanomedicine candidates for specific clinical applications. Key
properties influencing the biodistribution and pharmacokinetics of nanomedicines include
particle composition, size, shape, modulus, charge and surface characteristics [29]. These
properties also affect clearance routes and particle–target cell interaction, the latter of which
is crucial for internalization.
Surface modification can be used both to alter the particles’ physicochemical properties and
also to incorporate targeting moieties. Due to their high surface-to-volume ratio,
nanoparticles are particularly well suited to displaying targeting ligands on their surfaces in
a dense manner. Unlike current conventional imaging agents that cannot recognize more
than one biomarker, nanoparticles can be functionalized with multiple ligands to detect
several biomarkers simultaneously [30,31] and at much lower concentrations [32,33], thus
allowing for multiplexed anatomic and functional imaging [34].
Important considerations for biotargeted nanoparticles include the type of ligand, the
preferred ligand architecture and optimal stoichiometry/density per particle. Furthermore,
since there are many potential sites of attachment, the inherent heterogeneity of ligand
distribution on the surface of the nanoparticles must be recognized and addressed.
Controlled, reproducible surface modification remains a difficult task. Additionally, the
characterization of ligands, as well as the aforementioned parameters, is crucial. Table 1
highlights some common roadblocks and possible solutions in characterizing clinical and
preclinical nanoparticle formulations. Formulation often relies on self-assembly, and the
resultant particles can exhibit high poly-dispersity. Extrusion can be used to narrow the size
distribution [35], and templated manufacturing [29] and microfluidic-based flow focusing
are emerging strategies [36].
Critical issues to address in the formulation of drugs entrapped in nanoparticles include
entrapment efficiency, particle stability and drug release rate. Release kinetics represents a
particularly salient feature of particle-based formulations, which often demonstrate rapid
release of drug (‘burst release’) or very slow release. Mathematical models are being used to
predict drug release from bulk- and surface-eroding systems [37], and combinatorial library
screening followed by optimization can reveal pharmacokinetic profiles that are desirable
[38]. Novel drug-delivery systems have been designed to require an external stimulus to
trigger release [39,40], adding an extra level of control. Such advanced platforms can
combine spatial targeting with functional targeting.
Nanoparticles should be well characterized prior to application since batch-to-batch
variability continues to plague preclinical studies even in the most conscientious
laboratories. The National Cancer Institute’s (NCI) Nanotechnology Characterization
Laboratory (NCL) has been and continues to be a central player in developing reliable
assays to measure in vitro characteristics of complex nanoparticles, as well as
pharmacokinetic and toxicological profiles using animal models. The NCL has developed
reliable screens for full nanoparticle characterization, blood contact properties, in vitro
immunology and toxicity, as well as cell-based assays to assess inflammation, oxidative
stress and apoptosis/necrosis. Detailed protocols can be found on their website [105].
Following in vitro characterization, nanoparticles should be evaluated for pharmacokinetics,
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safety and efficacy in vivo. Moving forward, improved understanding of the underlying
mechanisms that dictate nanoparticle interactions with biological systems is critical.
Tenet 4: from one to millions
Large-scale manufacturing remains a costly and challenging aspect in the clinical translation
of biotargeted nanomedicines. Current clinically used nanomedicines have undergone long
development processes through contract research organizations to address potential issues
with scale-up. While making milligram quantities to test whether the technology is feasible
in the academic laboratory setting, scale-up manufacturing en route to obtaining high-quality
clinical-grade material can be intimidating for small firms and large companies alike.
While more challenges exist in the development of nanomedicines as compared with
traditional small-molecule drugs, it is possible to develop a robust approach that
incorporates current good manufacturing practices (GMP) with standardized and validated
synthetic, as well as analytical methods for the Chemistry, Manufacturing and Controls
section of an Investigational New Drug filing with the FDA. A thorough preclinical
investigation for biotargeted nanomedicines must include appropriate analytical,
bioanalytical and biochemical methods that identify and monitor nanomedicine components
that have the potential to trigger significant differences in biological end points, safety and
efficacy. Size distribution (in the dry state and in physiologically relevant solution), shape,
targeting ligand activity, coating uniformity and density, homogeneity of components,
surface charge/ζ-potential, therapeutic payload incorporation (free vs bound/encapsulated)
and release kinetics under biologically relevant conditions (Table 1) must all be analyzed
using standard operating procedures and validated methods.
Another important parameter for consideration in the manufacturing and scale-up of clinical
materials is preparation of the nanomedicine under sterile conditions and within the
allowable limits of endotoxin contamination. Initial preparation of the material under sterile
and endotoxin-free conditions is generally a better practice than post-manufacturing
purification, as this approach minimizes potential problems relating to nanoparticle
compatibility with sterilization techniques. Nanoparticle analysis pre- and post-sterilization
should include assays that verify consistency, functional integrity and reproducible
bioactivity or biological outcome.
For clinical production and pharmaceutical quality, a uniform product that is standardized
and can be manufactured with insignificant batch-to-batch variation is desired. This is often
difficult with nanoparticles, as an extremely controlled manufacturing environment is
needed, and the scale of production dictates the intricacies of the manufacturing process. A
recent FDA publication offers a chronology for nanotherapeutic development, and
manufacturing characterization is highlighted [41]. However, it is prudent not to wait until
the final GMP phase to consider how such a product can be made in order to meet current
GMP requirements.
Tenet 5: technology meets reality
Drug and imaging products that are developed for use in humans in the USA are subject to
regulatory review and approval by the FDA. The agency has formed a Nanotechnology Task
Force both to address regulatory and scientific issues and to draft guidance for researchers
and manufacturers [106]. Although the FDA has guidelines for what it considers to be a
nanoparticle [107], it has not yet articulated specific review criteria for nanoparticle-based
products. The FDA is evaluating products on a case-by-case basis, using the quality of
science as a key barometer. Issues relating to synthesis, characterization, pharmacology and
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toxicology, as well as the manufacturing facility, are of utmost importance for regulatory
approval to be granted.
Notably, materials previously approved for clinical use may have different properties from
the parent material when formulated at the nanoscale or when incorporated into a nanoscale
delivery platform. A well-characterized component, such as a small-molecule drug, needs to
be re-assessed when incorporated into a nanoparticle, since its known pharmacokinetic
profile no longer applies. Two fundamentally different components exist: the therapeutic
drug, often a small molecule and a well-defined compound from a structural perspective;
and the nanoparticle carrier, often comprising multiple components that may not be
homogeneous. The fate of each component must be tracked and assessed separately.
Moreover, the individual components may interact with one another or affect
characterization [42].
Each cancer type varies in how well animal models mimic the human disease, and different
species can exhibit differing absorption, distribution, metabolism, excretion and
toxicological profiles. Additionally, there are lingering questions as to what effects
extremely stable entities, such as quantum dots, might have on the body over extended time
periods. To date, the FDA has only issued specific guidance for liposomal drug entities
[108]; however, this guidance document is referenced for other nanomedicine products.
With respect to nanoparticle-based products, the guidance pertains to physicochemical
properties, manufacturing process, excipients, drug product specifications, stability,
(bio)analytical methods, pharmacokinetics and bioavailability, and labeling. While such
GMP-related issues are critical, the most important criterion for approval remains
unchanged: the new nanomedicine entity must demonstrate acceptable safety, purity and
efficacy, especially compared with the standard-of-care.
Tenet 6: at what cost?
Drug improvements and innovations in cancer medicines have traditionally been assessed
and analyzed with respect to safety and efficacy. An often overlooked factor is cost, which is
especially important in the face of ever increasing healthcare expenses. There are a number
of FDA-registered nanoparticle-based products on the market that can be compared directly
with their non-nanoparticle-based standard-of-care counterparts. These nanoparticle-based
formulations may not be more efficacious than their counterparts; however, the
nanoparticle-based formulation could reduce dose-limiting toxicities. Cost–effectiveness
analysis (CEA) addresses the cost-to-benefit ratio of a new therapy versus the standard-of-
care therapy and should not be confused with the risk/safety-to-benefit ratio analysis
commonly performed by the FDA.
CEA is currently used as a post-marketing measure for physicians and insurers in therapy
decision-making. CEA should also be used to determine whether to proceed with a
particular nanoparticle technology, including analysis of raw materials, manufacturing, and
therapeutic and safety outcomes. This may allow one to predict the financial implications of
the nanomedicine compared with standard therapies.
At present, there are few cost–benefit studies available for nanomedicine products. As an
example, the cost–effectiveness of Doxil® (Janssen Biotech Inc, PA, USA; PEGylated
liposomal doxorubicin) and Abraxane® (Celgene Corporation, NJ, USA; nano-albumin
bound paclitaxel) is evaluated compared with their conventional standard-of-care generic
alternatives, doxorubicin and paclitaxel, respectively. In 2009, the average cost per dose of
Doxil was US$5594 compared with $62–162 for doxorubicin, and the average cost per dose
for Abraxane was $5054 compared with $90–454 for paclitaxel [109]. It is worth noting that
Doxil and Abraxane have either exclusivity or patent protection, whereas doxorubicin and
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paclitaxel are generics and inherently demand a lower pricing structure. The risk and benefit
factors for both nanoparticle-based products versus their small-molecule counterparts have
been established [43] and are continuing to be elucidated in greater detail as more clinical
trials are conducted. Notable health- and cost-related benefits of Doxil and Abraxane are
lower cardiac toxicity and reduced vehicle toxicity, respectively. Although neither
nanomedicine products have shown an increase in overall patient survival, the reduction in
toxicities and their associated cost have largely justified the higher cost. Increasing pressure
to reduce healthcare costs puts an even greater burden on the nanomedicine innovator to
justify the real cost-to-benefit ratio, and CEA provides a needed tool to do so. Since
targeting approaches are designed to improve efficacy while reducing toxicity, targeted
nanotherapeutics have the potential to reduce overall healthcare cost of an illness despite the
higher cost of the therapeutic.
Many of the companies that are currently developing biotargeted cancer therapies are
smaller start-ups featuring pipelines based on technologies that were originally developed in
academic laboratories, rendering high development costs even more daunting. There is a
movement towards collaborative efforts between large and small pharma, government,
nonprofit agencies and venture capital firms to defray costs of new therapeutic development.
Biotargeted nanomedicines is one area that could significantly benefit from such an
approach to bridge ‘the valley of death’. Funding programs, such as the newly established
Small Business Innovation Research (SBIR) Bridge program, as well as several consortia
that address clinical trials costs, such as the Prostate Cancer Clinical Trials Consortium and
the NIH Biomarkers Consortium, will surely benefit both biomedicine developers and
patients. As an example of sharing the costs of clinical trials, the Biomarkers Consortium is
conducting two studies in which nine industry partners jointly contribute a total of $6.53
million and the NCI contributes an additional $3.75 million [110]. Likewise, in the area of
nanomedicine, the NCI has established a consortium, Translation of Nanotechnology in
Cancer (TONIC), to foster collaborative efforts between government, industry partners and
academic researchers.
An incentive for innovators of nanomedicine products is that approved biotargeted nano-
medicines are less prone to competition from generic companies, as it is very difficult to
demonstrate bioequivalence of a generic version of a nanomedicine owing to the
complexities of the product [44]. Thus, makers of safe, efficacious nanomedicines will
probably experience a steady or increasing demand for these therapeutics for many years,
potentially even after patent expiry.
Conclusion & future perspective
Biotargeted nanomedicines are now actively being investigated in human clinical trials. It is
likely that the first group of FDA-registered biotargeted nanomedicines will be niche
products that address specific applications. As the field continues to advance, however, we
foresee solutions to the complexities described herein through the application of rigorous
characterization techniques and utilization of the collected data to inform subsequent
iterations of nanomedicine design. By combining the principles of engineering, chemistry
and medicine – particularly in the context of an improved understanding of fundamental
biology – the field of nanotechnology will move closer to making the elusive ‘magic bullet’
a reality [45].
Acknowledgments
The authors would like to thank J Whitley, Creative Lead for Instructional Innovation in the Educational
Technology Research and Development Group at the UNC Eshelman School of Pharmacy, for his creation of
Figures 1 & 2.
Goldberg et al. Page 8














Papers of special note have been highlighted as:
▪ of interest
▪▪ of considerable interest
1. Nolan BW, Schermerhorn ML, Powell RJ, et al. Restenosis in gold-coated renal artery stents. J Vasc
Surg. 2005; 42(1):40–46. [PubMed: 16012450]
2. Park J-H, Von Maltzahn G, Xu MJ, et al. Cooperative nanomaterial system to sensitize, target, and
treat tumors. Proc Natl Acad Sci USA. 2010; 107(3):981–986. [PubMed: 20080556]
3. Park J, Gao W, Whiston R, Strom TB, Metcalfe S, Fahmy TM. Modulation of CD4+ T lymphocyte
lineage outcomes with targeted, nanoparticle-mediated cytokine delivery. Mol Pharm. 2011; 8(1):
143–152. [PubMed: 20977190]
4. Agemy L, Friedmann-Morvinski D, Kotamraju VR, et al. Targeted nanoparticle enhanced
proapoptotic peptide as potential therapy for glioblastoma. Proc Natl Acad Sci USA. 2011; 108(42):
17450–17455. [PubMed: 21969599]
5. Poon Z, Lee JA, Huang S, Prevost RJ, Hammond PT. Highly stable, ligand-clustered “patchy”
micelle nanocarriers for systemic tumor targeting. Nanomedicine (Lond). 2011; 7(2):201–209.
6. Yang L, Mao H, Cao Z, et al. Molecular imaging of pancreatic cancer in an animal model using
targeted multifunctional nanoparticles. Gastroenterology. 2009; 136(5):1514.e2–1525.e2. [PubMed:
19208341]
7. Yang L, Mao H, Wang YA, et al. Single chain epidermal growth factor receptor antibody
conjugated nanoparticles for in vivo tumor targeting and imaging. Small. 2009; 5(2):235–243.
[PubMed: 19089838]
8. McCarthy JR, Korngold E, Weissleder R, Jaffer FA. A light-activated theranostic nanoagent for
targeted macrophage ablation in inflammatory atherosclerosis. Small. 2010; 6(18):2041–2049.
[PubMed: 20721949]
9. Santra S, Kaittanis C, Santiesteban OJ, Perez JM. Cell-specific, activatable, and theranostic prodrug
for dual-targeted cancer imaging and therapy. J Am Chem Soc. 2011; 133(41):16680–16688.
[PubMed: 21910482]
10. Wang X, Li J, Wang Y, et al. A folate receptor-targeting nanoparticle minimizes drug resistance in
a human cancer model. ACS Nano. 2011; 5(8):6184–6194. [PubMed: 21728341]
11. Zhou J, Patel TR, Fu M, Bertram JP, Saltzman WM. Octa-functional PLGA nanoparticles for
targeted and efficient siRNA delivery to tumors. Biomaterials. 2012; 33(2):583–591. [PubMed:
22014944]
12. Yokoyama T, Tam J, Kuroda S, et al. EGFR-targeted hybrid plasmonic magnetic nanoparticles
synergistically induce autophagy and apoptosis in non-small cell lung cancer cells. PLoS One.
2011; 6(11):e25507. [PubMed: 22087216]
13. Alexis F, Basto P, Levy-Nissenbaum E, et al. HER-2-targeted nanoparticle–affibody bioconjugates
for cancer therapy. Chem Med Chem. 2008; 3(12):1839–1843. [PubMed: 19012296]
14. Savla R, Taratula O, Garbuzenko O, Minko T. Tumor targeted quantum dot-mucin 1 aptamer-
doxorubicin conjugate for imaging and treatment of cancer. J Control Release. 2011; 153(1):16–
22. [PubMed: 21342659]
15▪. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for
cancer. Nat Rev Drug Discov. 2008; 7(9):771–782. Comprehensive review highlighting major
classes of nanoparticles that have been investigated in human clinical trials. [PubMed: 18758474]
16. Van Oosten M, Crane LM, Bart J, Van Leeuwen FW, Van Dam GM. Selecting potential targetable
biomarkers for imaging purposes in colorectal cancer using Target Selection Criteria (TASC): a
novel target identification tool. Transl Oncol. 2011; 4(2):71–82. [PubMed: 21461170]
17. Yoon DJ, Liu CT, Quinlan DS, Nafisi PM, Kamei DT. Intracellular trafficking considerations in
the development of natural ligand–drug molecular conjugates for cancer. Ann Biomed Eng. 2011;
39(4):1235–1251. [PubMed: 21350890]
Goldberg et al. Page 9













18. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on
the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo
imaging. Proc Natl Acad Sci USA. 2007; 104(39):15549–15554. [PubMed: 17875985]
19. Kirpotin DB, Drummond DC, Shao Y, et al. Antibody targeting of long-circulating lipidic
nanoparticles does not increase tumor localization but does increase internalization in animal
models. Cancer Res. 2006; 66(13):6732–6740. [PubMed: 16818648]
20▪. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646–674.
Excellent report on the six complexities of human tumors including proliferative signaling,
evading growth suppressors, resisting cell death, enabling replicative immortality, inducing
angiogenesis and activating invasion and metastasis. [PubMed: 21376230]
21. Michor F, Polyak K. The origins and implications of intratumor heterogeneity. Cancer Prev Res
(Phila). 2010; 3(11):1361–1364. [PubMed: 20959519]
22. Scheel C, Eaton EN, Li SH-J, et al. Paracrine and autocrine signals induce and maintain
mesenchymal and stem cell states in the breast. Cell. 2011; 145(6):926–940. [PubMed: 21663795]
23▪. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;
7(11):653–664. Critical read to understand the challenges and opportunities in delivering drugs to
solid tumors using nanoparticles. [PubMed: 20838415]
24. Sengupta S, Eavarone D, Capila I, et al. Temporal targeting of tumour cells and neovasculature
with a nanoscale delivery system. Nature. 2005; 436(7050):568–572. [PubMed: 16049491]
25. Blanco E, Hsiao A, Mann AP, Landry MG, Meric-Bernstam F, Ferrari M. Nanomedicine in cancer
therapy: innovative trends and prospects. Cancer Sci. 2011; 102(7):1247–1252. [PubMed:
21447010]
26. Wong C, Stylianopoulos T, Cui J, et al. Multistage nanoparticle delivery system for deep
penetration into tumor tissue. Proc Natl Acad Sci USA. 2011; 108(6):2426–2431. [PubMed:
21245339]
27. Harris TJ, Von Maltzahn G, Lord ME, et al. Protease-triggered unveiling of bioactive
nanoparticles. Small. 2008; 4(9):1307–1312. [PubMed: 18690639]
28. Poon Z, Chang D, Zhao X, Hammond PT. Layer-by-layer nanoparticles with a pH-sheddable layer
for in vivo targeting of tumor hypoxia. ACS Nano. 2011; 5(6):4284–4292. [PubMed: 21513353]
29. Wang J, Byrne JD, Napier ME, Desimone JM. More effective nanomedicines through particle
design. Small. 2011; 7(14):1919–1931. [PubMed: 21695781]
30. Kennedy DC, Hoop KA, Tay L-L, Pezacki JP. Development of nanoparticle probes for multiplex
SERS imaging of cell surface proteins. Nanoscale. 2010; 2(8):1413–1416. [PubMed: 20820725]
31. Ko MH, Kim S, Kang WJ, et al. In vitro derby imaging of cancer biomarkers using quantum dots.
Small. 2009; 5(10):1207–1212. [PubMed: 19235198]
32. Gindy ME, Prud’homme RK. Multifunctional nanoparticles for imaging, delivery and targeting in
cancer therapy. Expert Opin Drug Deliv. 2009; 6(8):865–878. [PubMed: 19637974]
33. Thaxton CS, Elghanian R, Thomas AD, et al. Nanoparticle-based bio-barcode assay redefines
“undetectable” PSA and biochemical recurrence after radical prostatectomy. Proc Natl Acad Sci
USA. 2009; 106(44):18437–18442. [PubMed: 19841273]
34. Serda RE, Godin B, Blanco E, Chiappini C, Ferrari M. Multi-stage delivery nano-particle systems
for therapeutic applications. Biochim Biophys Acta. 2011; 1810(3):317–329. [PubMed: 20493927]
35. Hossann M, Wang T, Wiggenhorn M, et al. Size of thermosensitive liposomes influences content
release. J Control Release. 2010; 147(3):436–443. [PubMed: 20727921]
36. Rhee M, Valencia PM, Rodriguez MI, Langer R, Farokhzad OC, Karnik R. Synthesis of size-
tunable polymeric nanoparticles enabled by 3D hydrodynamic flow focusing in single-layer
microchannels. Adv Mater. 2011; 23(12):H79–H83. [PubMed: 21433105]
37. Rothstein SN, Federspiel WJ, Little SR. A unified mathematical model for the prediction of
controlled release from surface and bulk eroding polymer matrices. Biomaterials. 2009; 30(8):
1657–1664. [PubMed: 19101031]
38. Hrkach J, Von Hoff D, Ali MM, et al. Preclinical development and clinical translation of a PSMA-
targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med.
2012; 4(128):128–139.
Goldberg et al. Page 10













39. Ge J, Neofytou E, Cahill TJ, Beygui RE, Zare RN. Drug release from electric-field-responsive
nanoparticles. ACS Nano. 2012; 6(1):227–233. [PubMed: 22111891]
40. Melancon MP, Zhou M, Li C. Cancer theranostics with near-infrared light-activatable multimodal
nanoparticles. Acc Chem Res. 2011; 44(10):947–956. [PubMed: 21848277]
41▪. Tyner K, Sadrieh N. Considerations when submitting nanotherapeutics to FDA/CDER for
regulatory review. Methods Mol Biol. 2011; 697:17–31. Informative US FDA perspective on
how current FDA guidances apply to nanoparticles and nanotherapeutics. [PubMed: 21116951]
42. Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. Preclinical studies to understand
nanoparticle interaction with the immune system and its potential effects on nanoparticle
biodistribution. Mol Pharm. 2008; 5(4):487–495. [PubMed: 18510338]
43. Gaitanis A, Staal S. Liposomal doxorubicin and nAb-paclitaxel: nanoparticle cancer chemotherapy
in current clinical use. Methods Mol Biol. 2010; 624:385–392. [PubMed: 20217610]
44. Burgess P, Hutt PB, Farokhzad OC, Langer R, Minick S, Zale S. On firm ground: IP protection of
therapeutic nanoparticles. Nat Biotechnol. 2010; 28(12):1267–1270. [PubMed: 21139609]
45. Sharp PA, Langer R. Promoting convergence in biomedical science. Science. 2011; 333(6042):
527. [PubMed: 21798916]
46. Dobrovolskaia MA, Patri AK, Simak J, et al. Nanoparticle size and surface charge determine
effects of PAMAM dendrimers on human platelets in vitro. Mol Pharm. 2012; 9(3):382–393.
[PubMed: 22026635]
47. Stern ST, Hall JB, Yu LL, et al. Translational considerations for cancer nanomedicine. J Control
Release. 2010; 146(2):164–174. [PubMed: 20385183]
48. McNeil, SE., editor. Characterization of Nanoparticles Intended for Drug Delivery. Humana Press
Inc; NY, USA: 2011.
49. Roebben G, Ramirez-Garcia S, Hackley VA, et al. Interlaboratory comparison of size and surface
charge measurements on nanoparticles prior to biological impact assessment. J Nanopart Res.
2011; 13(7):2675–2687.
50. Boeckler C, Frisch B, Muller S, Schuber F. Immunogenicity of new heterobifunctional cross-
linking reagents used in the conjugation of synthetic peptides to liposomes. J Immunol Methods.
1996; 191(1):1–10. [PubMed: 8642195]
51. Leonov AP, Zheng J, Clogston JD, Stern ST, Patri AK, Wei A. Detoxification of gold nanorods by
treatment with polystyrenesulfonate. ACS Nano. 2008; 2(12):2481–2488. [PubMed: 19206282]
52. Zara J, Pomato N, McCabe RP, Bredehorst R, Vogel CW. Cobra venom factor immunoconjugates:
effects of carbohydrate-directed versus amino group-directed conjugation. Bioconjug Chem. 1995;
6(4):367–372. [PubMed: 7578355]
53. Lo ST, Stern S, Clogston JD, et al. Biological assessment of triazine dendrimer: toxicological
profiles, solution behavior, biodistribution, drug release and efficacy in a PEGylated, paclitaxel
construct. Mol Pharm. 2010; 7(4):993–1006. [PubMed: 20481608]
54. Zolnik BS, Stern ST, Kaiser JM, et al. Rapid distribution of liposomal short-chain ceramide in
vitro and in vivo. Drug Metab Dispos. 2008; 36(8):1709–1715. [PubMed: 18490436]
55. Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE. Nanoparticle interaction
with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic
efficacy. Adv Drug Deliv Rev. 2009; 61(6):428–437. [PubMed: 19376175]
56. Simanek E, Patri AK. Biodistribution of nanomedicines. Mol Pharm. 2008; 5(4):473. [PubMed:
18672948]
57. Dobrovolskaia MA, Clogston JD, Neun BW, Hall JB, Patri AK, McNeil SE. Method for analysis
of nanoparticle hemolytic properties in vitro. Nano Lett. 2008; 8(8):2180–2187. [PubMed:
18605701]
58. Dobrovolskaia MA, Germolec DR, Weaver JL. Evaluation of nanoparticle immunotoxicity. Nat
Nanotechnol. 2009; 4(7):411–414. [PubMed: 19581891]
59. Zolnik BS, Gonzalez-Fernandez A, Sadrieh N, Dobrovolskaia MA. Nanoparticles and the immune
system. Endocrinology. 2010; 151(2):458–465. [PubMed: 20016026]
Goldberg et al. Page 11














101. A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer. http://
clinicaltrials.gov/ct2/show/NCT01300533?term=NCT01300533&rank=1
102. Safety Study of CALAA-01 to Treat Solid Tumor Cancers. http://clinicaltrials.gov/ct2/show/
NCT00689065?term=NCT00689065&rank=1
103. Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal
Adenocarcinoma. http://clinicaltrials.gov/ct2/show/NCT00964080?term=NCT00964080&rank=1
104. Safety Study of Infusion of SGT-53 to Treat Solid Tumors. http://clinicaltrials.gov/ct2/show/
NCT00470613?term=NCT00470613&rank=1
105 ▪▪. National Cancer Institute’s Nanotechnology Characterization Laboratory. http://
ncl.cancer.gov/Very informative website that has excellent resources including assay cascades
and standard operating procedures for physical/chemical characterization and in vitro and in vivo
testing of nanoparticles
106. US FDA. Nanotechnology task force report. 2007. www.fda.gov/ScienceResearch/SpecialTopics/
Nanotechnology/UCM2006659.htm
107▪. US FDA. Guidance for industry: considering whether an FDA-regulated product involves the
application of nanotechnology. 2011. www.fda.gov/regulatoryinformation/guidances/
ucm257698.htmMust-read guidance that describes the FDA’s current thinking on whether FDA-
regulated products contain nanomaterials or otherwise involve the application of nanotechnology
108. US FDA. Guidance for industry: liposome drug products chemistry, manufacturing, and controls;
human pharmacokinetics and bioavailability; and labeling documentation. 2002. www.fda.gov/
downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070570.pdf
109. EvaluatePharma. Worldwide sales 2007–2009. 2011. www.evaluatepharma.com
110. The Biomarkers Consortium. www.biomarkersconsortium.org/
Goldberg et al. Page 12














Tenet 1: sights on the targe
• The selection of the appropriate target for biotargeted nanomedicines is critical
for successful outcomes.
Tenet 2: leaping biological hurdles
• The validation of new targets is important, but the complexity of tumor biology
must also be recognized.
Tenet 3: these are not tablets
• The ability to control the material properties of nanomedicines remains a major
obstacle to the realization of the potential of medical nanotechnology.
Tenet 4: from one to millions
• A thorough investigation for biotargeted nanomedicines must include
appropriate analytical, bioanalytical and biochemical methods.
Tenet 5: technology meets reality
• The new nanomedicine entity must demonstrate acceptable safety, purity and
efficacy, especially compared with the standard-of-care.
Tenet 6: at what cost?
• The nanomedicine innovator must justify the real cost-to-benefit ratio of their
new nanomedicine as compared with the standard-of-care.
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Sequential barriers and opportunities for targeting a nanomedicine to cancer.
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Transport of nanoparticles from the vasculature into the tumor parenchyma and hypoxic
core.
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Table 1
Common roadblocks to the realization of biotargeted nanomedicines
Characterization parameters Common roadblock Possible solutions Ref.
Biological activity/ potency Difficulties characterizing a number of
ligands on the surface of the nanoparticles,
including orientation and activity. Changes in
the manufacturing process can readily alter
these parameters
Characterization is key. Multiple orthogonal
methods should be applied to evaluate batch-to-
batch consistency. ζ-potential and microscopy
methods can be evaluated to probe nanoparticle
surface. Whenever possible, nanomedicines
should be evaluated using functional bioassays
[46,47]
Polydispersity/ heterogeneity Individual molecules of a nanoparticle can
contain hundreds or even thousands of atoms.
Therefore, many possible permutations in the
arrangement and chemical attachment leads
to an inherent structural heterogeneity, even
in a ‘pure’ nanomedicine
Nanomedicine properties must be defined by an
acceptable range that affords the necessary
safety and efficacy profile for the nanoparticle
formulation rather than by an absolute standard
[48,49]
Biocompatibility Non-API components of the nanoparticles
cause adverse effects (e.g., surfactants used in
synthesis may be cytotoxic or linkers used to
attach targeting ligands may be immunotoxic)
The inclusion of appropriate controls in
cytotoxicity tests, including those that
distinguish and compare the toxicity of various
components of a nanomedicine (i.e., buffer,
supernatant/ filtrate, platform and linker
molecules), may illuminate toxicity due to non-
API components
[50–52]
In vivo stability The drug and nanoparticle do not stay
associated in vivo, and/or the rate of drug
release may be rapid
Dual radiolabeling of drug and nanoparticle as
well as in vitro release assays that predict in vivo
fate (i.e., release assays in whole blood or 100%
plasma) can be highly informative
[52–54]
Biodistribution Rapid uptake from the systemic circulation
by cells of the immune system (MPS)
Coating with hydrophilic polymers such as PEG
can reduce interactions with plasma proteins and
uptake by MPS cells
[55,56]
Immune reactions Nanoparticles may cause platelet aggregation,
hemolysis, coagulation, activation of the
complement system or innate and/or adaptive
responses
Robust in vitro assays for hematological
interactions and immunological responses
should be used to screen for such effects early in
preclinical development
[57–59]
API: Active pharmaceutical ingredient; MPS: Mononuclear phagocytic system; PEG: Polyethylene glycol.
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